List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4332546/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Application of citicoline in supporting therapy of selected diseases. Acta Poloniae Pharmaceutica, 2022, 78, 591-598.	0.3	2
2	New 1,2,4-oxadiazole derivatives with positive mGlu ₄ receptor modulation activity and antipsychotic-like properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 211-225.	2.5	3
3	Neurotoxicity in Depression. , 2021, , 1-30.		0
4	Pharmaco-Electroencephalography-Based Assessment of Antidepressant Drug Efficacy—The Use of Magnesium Ions in the Treatment of Depression. Journal of Clinical Medicine, 2021, 10, 3135.	1.0	2
5	Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy, 2020, 21, 9-20.	0.9	47
6	Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets. Expert Opinion on Therapeutic Targets, 2020, 24, 1187-1209.	1.5	11
7	The functional cooperation of 5-HT1A and mGlu4R in HEK-293 cell line. Pharmacological Reports, 2020, 72, 1358-1369.	1.5	2
8	Developments in the discovery and design of intranasal antidepressants. Expert Opinion on Drug Discovery, 2020, 15, 1145-1164.	2.5	9
9	The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. Schizophrenia Bulletin, 2020, 46, 1471-1481.	2.3	20
10	Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacological Reports, 2020, 72, 543-562.	1.5	82
11	Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. , 2019, 193, 75-82.		11
12	Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. Behavioural Pharmacology, 2019, 30, 471-477.	0.8	22
13	Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries. Frontiers in Pharmacology, 2019, 10, 1279.	1.6	12
14	Simultaneous activation of muscarinic and GABAB receptors as a bidirectional target for novel antipsychotics. Behavioural Brain Research, 2019, 359, 671-685.	1.2	14
15	Breast cancer surgery decreases serum brain-derived neurotrophic factor concentrations in middle aged women: relationship to the serum C-reactive protein concentration. Journal of Physiology and Pharmacology, 2019, 70, .	1.1	2
16	Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics, 2018, 36, 853-865.	1.7	14
17	Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatology International, 2018, 38, 189-201.	1.5	45
18	Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrobial Resistance and Infection Control, 2018, 7, 136.	1.5	54

#	Article	IF	CITATIONS
19	Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment. Frontiers in Pharmacology, 2018, 9, 1263.	1.6	25
20	Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs. Frontiers in Molecular Neuroscience, 2018, 11, 316.	1.4	23
21	Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Archives of Medical Science, 2018, 14, 1125-1136.	0.4	37
22	New evidences for a role of mGluR7 in astrocyte survival: Possible implications for neuroprotection. Neuropharmacology, 2018, 141, 223-237.	2.0	14
23	Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Frontiers in Pharmacology, 2018, 9, 621.	1.6	9
24	Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents. Psychopharmacology, 2018, 235, 2897-2913.	1.5	20
25	Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response. Nutrients, 2018, 10, 1014.	1.7	16
26	The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. Neuropharmacology, 2018, 141, 214-222.	2.0	16
27	Neurochemical changes underlying schizophrenia-related behavior in a modified forced swim test in mice. Pharmacology Biochemistry and Behavior, 2018, 172, 50-58.	1.3	11
28	Serotonin transporter and receptor ligands with antidepressant activity as neuroprotective and proapoptotic agents. Pharmacological Reports, 2017, 69, 469-478.	1.5	18
29	The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 385-400.	0.7	7
30	Co-administration of COX-2 inhibitor NS-398 enhances antidepressant effect of mGluR5 antagonist MTEP in mice. European Neuropsychopharmacology, 2017, 27, S9-S10.	0.3	0
31	The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 155-161.	2.5	23
32	Neurochemical and behavioral studies on the 5-HT 1A -dependent antipsychotic action of the mGlu 4 receptor agonist LSP4-2022. Neuropharmacology, 2017, 115, 149-165.	2.0	22
33	Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Clinical Drug Investigation, 2017, 37, 25-37.	1.1	14
34	NS-398 potentiates the antidepressant-like effect of MTEP in mice: involvement of pro-inflammatory cytokine pathways in the brain. European Neuropsychopharmacology, 2017, 27, S769-S770.	0.3	0
35	Chronic co-administration of mGluR5 antagonist (MTEP) with COX-2 inhibitor (NS398) affects DSCAM expression in prefrontal cortex and hippocampus in C57Bl/6J mice. European Neuropsychopharmacology, 2017, 27, S771.	0.3	1
36	The involvement of GABAB receptors in antipsychotic-like effects of positive allosteric modulator of muscarinic acetylcholine M4 receptors. European Neuropsychopharmacology, 2017, 27, S965-S966.	0.3	0

#	Article	IF	CITATIONS
37	Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Frontiers in Pharmacology, 2017, 8, 892.	1.6	27
38	Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland. Przeglad Gastroenterologiczny, 2017, 1, 60-65.	0.3	7
39	An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Archives of Medical Science, 2016, 5, 1097-1109.	0.4	16
40	Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland. PLoS ONE, 2016, 11, e0168586.	1.1	22
41	Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. Archives of Medical Science, 2016, 5, 1088-1096.	0.4	12
42	Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatology International, 2016, 36, 1223-1230.	1.5	15
43	Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. Translational Psychiatry, 2016, 6, e827-e827.	2.4	13
44	Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy, 2016, 36, 472-481.	1.2	8
45	Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. Pharmacotherapy, 2016, 36, 861-869.	1.2	3
46	Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. Pharmacotherapy, 2016, 36, 870-879.	1.2	17
47	The Transparency Of Published Recommendations On Reimbursement Of Health Technologies In Poland. Value in Health, 2016, 19, A447-A448.	0.1	0
48	The possible role of mGluR4 in drug addiction. European Neuropsychopharmacology, 2016, 26, S125-S126.	0.3	0
49	Over-the-counter medicine and dietary supplement consumption among academic youth in Poland. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 199-205.	0.7	7
50	The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Orphanet Journal of Rare Diseases, 2016, 11, 122.	1.2	31
51	Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis. Pharmacological Reports, 2016, 68, 1237-1243.	1.5	28
52	Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European Journal of Clinical Pharmacology, 2016, 72, 1319-1325.	0.8	7
53	Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology, 2016, 111, 169-179.	2.0	31
54	The usefulness of monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients. Pharmacological Reports, 2016, 68, 1120-1125.	1.5	10

#	Article	IF	CITATIONS
55	Glutamate-Based Drug Discovery for Novel Antidepressants. Expert Opinion on Drug Discovery, 2016, 11, 873-883.	2.5	14
56	Systemic Solutions, Legislative And Organizational Frameworks Aimed To Prevent Or Mitigate Drug Shortages In European Countries. Value in Health, 2016, 19, A445.	0.1	1
57	Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology, 2016, 233, 2901-2914.	1.5	37
58	Expression of group III metabotropic glutamate receptors in the reproductive system of male mice. Reproduction, Fertility and Development, 2016, 28, 369.	0.1	13
59	Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. , 2016, 157, 10-27.		44
60	Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PLoS ONE, 2016, 11, e0160444.	1.1	7
61	Involvement of GABA _B Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu ₄ Receptor, LSP4-2022. Current Neuropharmacology, 2016, 14, 413-426.	1.4	25
62	Abstract WP425: Blood Brain Barrier Disruption and Vascular Cognitive Impairment in Early Stages of Heart Failure Development in Tgαq*44 Mice. Stroke, 2016, 47, .	1.0	0
63	P.2.a.008 Pro-depressive-like effects of mGlu4 selective agonist LSP4–2022 in mice. European Neuropsychopharmacology, 2015, 25, S379.	0.3	0
64	Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0124279.	1.1	25
65	A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the European Union's Perspectives. PLoS ONE, 2015, 10, e0125691.	1.1	59
66	Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. International Journal of Molecular Sciences, 2015, 16, 18474-18506.	1.8	76
67	Tetracycline-Based System for Controlled Inducible Expression of Group III Metabotropic Glutamate Receptors. Journal of Biomolecular Screening, 2015, 20, 350-358.	2.6	8
68	Neuroprotective effects of mGluR II and III activators against staurosporine- and doxorubicin-induced cellular injury in SH-SY5Y cells: New evidence for a mechanism involving inhibition of AIF translocation. Neurochemistry International, 2015, 88, 124-137.	1.9	20
69	The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies. Psychopharmacology, 2015, 232, 259-273.	1.5	25
70	mGlu5-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia. Neurochemistry International, 2015, 88, 97-109.	1.9	24
71	A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action. Neuropharmacology, 2015, 97, 338-345.	2.0	26
72	Pregabalin for the treatment of social anxiety disorder. Expert Opinion on Investigational Drugs, 2015, 24, 585-594.	1.9	18

#	Article	IF	CITATIONS
73	Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 254-263.	2.5	43
74	Prolonged administration of antidepressant drugs leads to increased binding of [3H]MPEP to mGlu5 receptors. Neuropharmacology, 2014, 84, 46-51.	2.0	15
75	Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: The impact of cell differentiation state. Neuropharmacology, 2014, 83, 36-53.	2.0	61
76	NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs, 2014, 23, 1181-1192.	1.9	40
77	The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. Psychopharmacology, 2014, 231, 97-107.	1.5	23
78	Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats. Neuropharmacology, 2014, 83, 28-35.	2.0	15
79	Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology, 2014, 82, 59-68.	2.0	40
80	Inhibitory actions of mGlu4 receptor ligands on cocaine-, but not nicotine-, induced sensitizing and conditioning locomotor responses in rats. Pharmacological Reports, 2014, 66, 205-211.	1.5	12
81	Role of Neurotoxicity in Depression. , 2014, , 1567-1593.		1
82	The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. Current Neuropharmacology, 2014, 12, 256-268.	1.4	17
83	The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling. Psychopharmacology, 2013, 227, 711-725.	1.5	29
84	The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clinical Rheumatology, 2013, 32, 1415-1424.	1.0	53
85	mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology, 2013, 66, 40-52.	2.0	105
86	Zinc deficiency alters responsiveness to antidepressant drugs in mice. Pharmacological Reports, 2013, 65, 579-592.	1.5	32
87	The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu2/3 receptor agonist, LY379268, is 5-HT1A dependent. Behavioural Brain Research, 2013, 256, 298-304.	1.2	35
88	Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu4 receptor. Neuropharmacology, 2013, 66, 225-235.	2.0	39
89	Glutamate-based anxiolytic ligands in clinical trials. Expert Opinion on Investigational Drugs, 2013, 22, 1007-1022.	1.9	17
90	Is the mGlu5 receptor a possible target for new antidepressant drugs?. Pharmacological Reports, 2013, 65, 1506-1511.	1.5	27

#	Article	IF	CITATIONS
91	Oxidative stress markers in affective disorders. Pharmacological Reports, 2013, 65, 1558-1571.	1.5	110
92	Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacological Reports, 2013, 65, 991-997.	1.5	35
93	Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. Journal of Affective Disorders, 2013, 151, 924-931.	2.0	63
94	Glutamate-Based Antidepressants: Preclinical Psychopharmacology. Biological Psychiatry, 2013, 73, 1125-1132.	0.7	104
95	The antipsychoticâ€like effects of positive allosteric modulators of metabotropic glutamate m <scp>G</scp> lu ₄ receptors in rodents. British Journal of Pharmacology, 2013, 169, 1824-1839.	2.7	44
96	A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats. Behavioural Brain Research, 2013, 238, 109-112.	1.2	24
97	Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and) Tj ETQq1 1 0. 2013, 5, 765-779.	784314 rg 0.4	BT /Overloc 69
98	Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2013, 8, e76587.	1.1	9
99	Investigational NMDA receptor modulators for depression. Expert Opinion on Investigational Drugs, 2012, 21, 91-102.	1.9	44
100	mGlu4-dependent reversal of the MK-801-induced cognitive impartment involves 5-HT1A receptors. Pharmacological Reports, 2012, 64, 486.	1.5	0
101	Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacological Reports, 2012, 64, 567-575.	1.5	62
102	On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice. Neuropharmacology, 2012, 62, 322-331.	2.0	21
103	Simultaneous alterations of brain and plasma serotonin concentrations and liver cytochrome P450 in rats fed on a tryptophan-free diet. Pharmacological Research, 2012, 66, 292-299.	3.1	14
104	Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 102-106.	2.5	23
105	A bright future of researching AMPA receptor agonists for depression treatment. Expert Opinion on Investigational Drugs, 2012, 21, 583-585.	1.9	3
106	Systematic review/Meta-analysis Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Archives of Medical Science, 2012, 5, 767-775.	0.4	40
107	Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology, 2012, 220, 481-494.	1.5	58
108	Different pattern of changes in calcium binding proteins immunoreactivity in the medial prefrontal cortex of rats exposed to stress models of depression. Pharmacological Reports, 2011, 63, 1539-1546.	1.5	24

#	Article	IF	CITATIONS
109	Anxiolytic-like activity of zinc in rodent tests. Pharmacological Reports, 2011, 63, 1050-1055.	1.5	32
110	Adjustment of adenylate cyclase [EC 4.6.1.1] activity in HEK293 cells transiently expressing mGluRs group III. Pharmacological Reports, 2011, 63, 578-579.	1.5	0
111	Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin-and GABA-dependent. Pharmacological Reports, 2011, 63, 880-887.	1.5	10
112	Spaced electroconvulsive treatment: effects on responses associated with α2- and 5-HT2–receptors. Journal of Pharmacy and Pharmacology, 2011, 35, 326-328.	1.2	11
113	Opiates and specific receptor binding of [3H]clonidine. Journal of Pharmacy and Pharmacology, 2011, 32, 70-71.	1.2	20
114	The GABA _B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. British Journal of Pharmacology, 2011, 163, 1034-1047.	2.7	28
115	Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortex. Amino Acids, 2011, 40, 249-258.	1.2	23
116	On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology, 2010, 212, 523-535.	1.5	51
117	The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids, 2010, 39, 205-217.	1.2	77
118	GABAergic dysfunction in mGlu7 receptor-deficient mice as reflected by decreased levels of glutamic acid decarboxylase 65 and 67kDa and increased reelin proteins in the hippocampus. Brain Research, 2010, 1334, 12-24.	1.1	22
119	Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. Journal of Affective Disorders, 2010, 126, 447-452.	2.0	111
120	The Antidepressant-Like Action of Metabotropic Glutamate 7 Receptor Agonist N,N′-Bis(Diphenylmethyl)-1,2-Ethanediamine (AMN082) Is Serotonin-Dependent. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 1066-1074.	1.3	50
121	Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology, 2010, 59, 627-634.	2.0	53
122	Alterations in hippocampal calcium-binding neurons induced by stress models of depression: a preliminary assessment. Pharmacological Reports, 2010, 62, 1204-1210.	1.5	31
123	NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacological Reports, 2010, 62, 1186-1190.	1.5	42
124	Ionic Glutamate Modulators in Depression (Zinc, Magnesium). , 2010, , 21-38.		4
125	Metabotropic Approaches to Anxiety. , 2010, , 157-173.		1
126	Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. Journal of Affective Disorders, 2009, 118, 187-195.	2.0	176

#	Article	IF	CITATIONS
127	The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology, 2009, 57, 227-234.	2.0	37
128	The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 323-329.	2.5	117
129	Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1454-1457.	2.5	10
130	Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochemistry International, 2009, 55, 85-97.	1.9	87
131	Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors. Pharmacological Reports, 2009, 61, 1184-1191.	1.5	49
132	The use of citation indicators to identify and support high-quality research in Poland. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 381-384.	1.0	9
133	Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test. Journal of Neural Transmission, 2008, 115, 829-830.	1.4	13
134	Antidepressant-like activity of zinc: further behavioral and molecular evidence. Journal of Neural Transmission, 2008, 115, 1621-1628.	1.4	110
135	Lack of NMDA–AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. Journal of Neural Transmission, 2008, 115, 1519-1520.	1.4	25
136	Mood disorders: Regulation by metabotropic glutamate receptors. Biochemical Pharmacology, 2008, 75, 997-1006.	2.0	164
137	Effects of South African traditional medicine in animal models for depression. Journal of Ethnopharmacology, 2008, 119, 542-548.	2.0	47
138	Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology, 2008, 55, 517-524.	2.0	45
139	Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behavioural Pharmacology, 2008, 19, 597-603.	0.8	65
140	Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacological Reports, 2008, 60, 588-9.	1.5	105
141	Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacological Reports, 2008, 60, 844-55.	1.5	27
142	D-serine, a selective glycine/N-methyl-D-aspartate receptor agonist, antagonizes the antidepressant-like effects of magnesium and zinc in mice. Pharmacological Reports, 2008, 60, 996-1000.	1.5	24
143	Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology, 2007, 52, 306-312.	2.0	35
144	Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent. Neuropharmacology, 2007, 53, 741-748.	2.0	30

#	Article	IF	CITATIONS
145	The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience, 2007, 145, 611-620.	1.1	42
146	Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Research, 2007, 1184, 88-95.	1.1	29
147	NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacology Biochemistry and Behavior, 2007, 88, 158-164.	1.3	69
148	Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. , 2007, 115, 116-147.		208
149	Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology, 2007, 194, 555-562.	1.5	132
150	Metabotropic glutamate receptors. Amino Acids, 2007, 32, 165-167.	1.2	1
151	Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids, 2007, 32, 169-172.	1.2	54
152	An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids, 2007, 32, 179-188.	1.2	57
153	Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacological Reports, 2007, 59, 595-600.	1.5	30
154	Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacological Reports, 2007, 59, 757-62.	1.5	26
155	Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. British Journal of Pharmacology, 2006, 149, 581-590.	2.7	60
156	Increase in synaptic hippocampal zinc concentration following chronic but not acute zinc treatment in rats. Brain Research, 2006, 1090, 69-75.	1.1	18
157	Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacological Reports, 2006, 58, 427-30.	1.5	34
158	Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacological Reports, 2006, 58, 820-6.	1.5	26
159	Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice. Pharmacology Biochemistry and Behavior, 2005, 81, 524-529.	1.3	39
160	Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacology Biochemistry and Behavior, 2005, 81, 901-906.	1.3	122
161	MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology, 2005, 49, 447-455.	2.0	46
162	The involvement of glutamate in the pathophysiology of depression. Drug News and Perspectives, 2005, 18, 262.	1.9	76

#	Article	IF	CITATIONS
163	GABA-ergic hypotheses of anxiety and depression: Focus on GABA-B receptor. Drugs of Today, 2005, 41, 755.	0.7	72
164	Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacological Reports, 2005, 57, 654-8.	1.5	35
165	Zinc and depression. An update. Pharmacological Reports, 2005, 57, 713-8.	1.5	106
166	Lack of the antianxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats. Pharmacological Reports, 2005, 57, 856-60.	1.5	24
167	Application of magnetic resonance diffusion anisotropy imaging for the assessment neuroprotecting effects of MPEP, a selective mGluR5 antagonist, on the rat spinal cord injury in vivo. Pharmacological Reports, 2005, 57, 861-6.	1.5	6
168	In the Amygdala Anxiolytic Action of mGlu5 Receptors Antagonist MPEP Involves Neuropeptide Y but not GABAA Signaling. Neuropsychopharmacology, 2004, 29, 514-521.	2.8	44
169	Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacology Biochemistry and Behavior, 2004, 78, 7-12.	1.3	104
170	Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. European Journal of Pharmacology, 2004, 492, 57-59.	1.7	63
171	Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. European Journal of Pharmacology, 2004, 498, 153-156.	1.7	51
172	Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology, 2004, 46, 151-159.	2.0	125
173	Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology, 2004, 47, 342-350.	2.0	87
174	Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms. Polish Journal of Pharmacology, 2004, 56, 863-6.	0.3	13
175	Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology, 2003, 165, 245-251.	1.5	54
176	Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Research Bulletin, 2003, 61, 159-164.	1.4	153
177	LY-354740 (Eli Lilly). IDrugs: the Investigational Drugs Journal, 2003, 6, 66-71.	0.7	8
178	Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Polish Journal of Pharmacology, 2003, 55, 455-9.	0.3	20
179	Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Polish Journal of Pharmacology, 2003, 55, 1143-7.	0.3	107
180	Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology, 2002, 42, 1016-1023.	2.0	51

#	Article	IF	CITATIONS
181	Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology, 2002, 43, 181-187.	2.0	147
182	Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacology Biochemistry and Behavior, 2002, 73, 327-332.	1.3	91
183	The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group Il metabotropic glutamate receptors. Brain Research, 2002, 950, 88-94.	1.1	10
184	The role of striatal metabotropic glutamate receptors in Parkinson's disease. Amino Acids, 2002, 23, 193-198.	1.2	23
185	In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: Review article. Amino Acids, 2002, 23, 207-211.	1.2	46
186	Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids, 2002, 23, 213-216.	1.2	61
187	A role for glutamate in the treatment of anxiety and depression: Focus on group I metabotropic glutamate (mGlu) receptors. Drugs of the Future, 2002, 27, 753.	0.0	17
188	On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Polish Journal of Pharmacology, 2002, 54, 581-6.	0.3	21
189	Interaction of zinc with antidepressants in the forced swimming test in mice. Polish Journal of Pharmacology, 2002, 54, 681-5.	0.3	42
190	Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Polish Journal of Pharmacology, 2002, 54, 707-10.	0.3	29
191	Antidepressant-like properties of zinc in rodent forced swim test. Brain Research Bulletin, 2001, 55, 297-300.	1.4	137
192	Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 2001, 41, 413-420.	2.0	106
193	The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology, 2001, 158, 94-99.	1.5	84
194	Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology, 2001, 132, 1423-1430.	2.7	295
195	(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. Brain Research, 2001, 903, 177-184.	1.1	9
196	Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. British Journal of Pharmacology, 2000, 130, 1425-1431.	2.7	39
197	Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 283-288.	1.4	46
198	Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats. Amino Acids, 2000, 19, 81-86.	1.2	8

#	Article	IF	CITATIONS
199	The role of glutamate receptors in antipsychotic drug action. Amino Acids, 2000, 19, 87-94.	1.2	39
200	The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids, 2000, 19, 95-101.	1.2	27
201	Differential effects of NMDA–receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology, 2000, 39, 631-642.	2.0	31
202	The effect of prolonged imipramine and electroconvulsive shock treatment on calcium/calmodulin-dependent protein kinase II in the hippocampus of rat brain. Neuropharmacology, 1999, 38, 597-603.	2.0	26
203	Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology, 1999, 38, 1831-1839.	2.0	123
204	LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 500-502.	1.4	85
205	Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. European Journal of Pharmacology, 1998, 349, 83-87.	1.7	33
206	The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. European Journal of Pharmacology, 1997, 319, 153-156.	1.7	50
207	The enhancement and the inhibition of noradrenaune-induced cyclic amp accumulation in rat brain by stimulation of metabotropic glutamate receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 673-690.	2.5	5
208	The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. NeuroReport, 1995, 7, 85-88.	0.6	17
209	The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. NeuroReport, 1995, 7, 85-88.	0.6	14
210	Trans-(±)-1-amino-1, 3-cyclopentanedicarboxylate (trans-ACPD) stimulates cAMP accumulation in rat cerebral cortical slices but not in glial or neuronal cell cultures. Neuroscience Letters, 1994, 169, 171-174.	1.0	2
211	N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible receptor inactivator, as a tool for measurement of α2-adrenoceptor occupancy in vivo. European Journal of Pharmacology, 1992, 212, 109-111.	1.7	9
212	Pretreatment with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline accelerates the electroshock-induced decrease in density of β-adrenoceptors but not functional downregulation. Neuropharmacology, 1990, 29, 469-473.	2.0	6
213	An in vivo procedure for the selective inactivation of rat brain cerebral cortical α-adrenoceptors using N-ethoxycarbonyl-2-ethoxy1,2-dihydroquinoline (EEDQ). Brain Research, 1989, 493, 8-13.	1.1	10
214	Reserpinization enhances electroconvulsive treatment effects on cortical α1-adrenoceptors. European Journal of Pharmacology, 1988, 157, 231-234.	1.7	3
215	Supersensitive?-adrenergic receptors are down-regulated in rat brain by mianserin administration. Journal of Neural Transmission, 1987, 70, 71-79.	1.4	4
216	Antidepressant administration has a differential effect on rat brain α2-adrenoceptor sensitivity to agonists and antagonists. European Journal of Pharmacology, 1986, 132, 277-282.	1.7	13

#	Article	IF	CITATIONS
217	Synergistic interaction between α- and β -adrenergic receptors in rat brain slices: Possible site for antidepressant drug action. Life Sciences, 1985, 37, 1183-1194.	2.0	30
218	Chronic antidepressants and GABA "B―receptors: A GABA hypothesis of antidepressant drug action. Life Sciences, 1984, 35, 2149-2154.	2.0	109
219	Electroshock-induced increase in [3H]prazosin binding to cortical membranes in reserpinized rats. European Journal of Pharmacology, 1984, 98, 429-431.	1.7	9
220	Chronic antidepressants and GABA synapses. Neuropharmacology, 1984, 23, 841-842.	2.0	17
221	Chronic treatment with imipramine: Further functional evidence for the enhanced noradrenergic transmission in flexor reflex activity. Naunyn-Schmiedeberg's Archives of Pharmacology, 1983, 322, 256-260.	1.4	47
222	Chronic electroconvulsive treatment enhances the density of [3H]prazosin binding sites in the central nervous system of the rat. Brain Research, 1983, 275, 392-395.	1.1	62
223	The attenuation by chronic electroconvulsive treatment of hypothermia induced by histamine H2-receptor stimulants in rats. European Journal of Pharmacology, 1983, 88, 255-257.	1.7	4
224	Attenuation by chronic imipramine treatment of [3H]clonidine binding to cortical membranes and of clonidine-induced hypothermia: the influence of central chemosympathectomy. Brain Research, 1982, 238, 499-504.	1.1	58
225	Histidine-induced bizarre behaviour in rats: The possible involvement of central cholinergic system. Neuropharmacology, 1982, 21, 781-785.	2.0	11
226	Depression by chronic electroconvulsive treatment of clonidine hypotherma and [3H]clonidine binding to rat cortical membranes. European Journal of Pharmacology, 1982, 80, 109-113.	1.7	86
227	Postdecapitation convulsions in the rat measured with an animex motility meter: Relation to central α-adrenoceptors. European Journal of Pharmacology, 1982, 85, 269-275.	1.7	34
228	Cataleptogenic doses of morphine suppress 3H-spiroperidol binding to striatal membranes. Naunyn-Schmiedeberg's Archives of Pharmacology, 1982, 319, 140-141.	1.4	1
229	Enhancement of responsiveness of the central serotonergic system and serotonin-2 receptor density in rat frontal cortex by electroconvulsive treatment. European Journal of Pharmacology, 1981, 76, 81-85.	1.7	111
230	Rapid-eye-movement sleep deprivation inhibits clonidine-induced sedation in rats. European Journal of Pharmacology, 1981, 71, 123-126.	1.7	16
231	Some central effects of impromidine, a potent agonist of histamine H2 receptors. Neuropharmacology, 1980, 19, 947-950.	2.0	6
232	The influence of 4-methylhistamine, an agonist of histamine H2 receptors on body temperature in rats. Neuropharmacology, 1980, 19, 773-775.	2.0	18
233	A possible serotoninergic link in the hypothermic action of histamine. Agents and Actions, 1979, 9, 87-88.	0.7	11
234	The influence of histamine H2-receptor antagonists on monoaminergic systems in rat brain. Agents and Actions, 1979, 9, 88-89.	0.7	3

ANDRZEJ PILC

#	Article	IF	CITATIONS
235	Influence of histamine on the serotonergic system of rat brain. European Journal of Pharmacology, 1979, 55, 269-272.	1.7	14
236	Two possible binding sites for3H-clonidine in the rat cerebral cortex. European Journal of Pharmacology, 1979, 58, 95-96.	1.7	9
237	Negligible binding of 3H-clonidine to histamine H2 receptor. European Journal of Pharmacology, 1979, 56, 177-178.	1.7	9
238	An interaction of histamine H2-receptor antagonists with the noradrenergic system in rat brain. European Journal of Pharmacology, 1978, 51, 71-75.	1.7	9
239	Direct or indirect action of histamine on dopamine metabolism in the rat striatum?. European Journal of Pharmacology, 1977, 46, 171-175.	1.7	7
240	Does histamine interact with cholinergic neurones in its cataleptogenic action in the rat?. Neuropharmacology, 1977, 16, 841-847.	2.0	29
241	SEPARATION OF ACETYLCHOLINE AND CATECHOLAMINE CONTAINING SYNAPTIC VESICLES FROM BRAIN CORTEX. Journal of Neurochemistry, 1977, 29, 449-459.	2.1	20
242	Histamine content and synthesis in central and pheripheral nerve structures during stress. Agents and Actions, 1975, 5, 4-8.	0.7	24
243	Catalepsia-like symptoms produced by histidine in rats. Agents and Actions, 1973, 3, 185-186.	0.7	15
244	Depression Viewed as a GABA/Glutamate Imbalance in the Central Nervous System. , 0, , .		2